CN114231489A - 用于重编程的功能性片段、组合及其应用 - Google Patents

用于重编程的功能性片段、组合及其应用 Download PDF

Info

Publication number
CN114231489A
CN114231489A CN202010934192.9A CN202010934192A CN114231489A CN 114231489 A CN114231489 A CN 114231489A CN 202010934192 A CN202010934192 A CN 202010934192A CN 114231489 A CN114231489 A CN 114231489A
Authority
CN
China
Prior art keywords
ser
ala
pro
expression
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010934192.9A
Other languages
English (en)
Chinese (zh)
Inventor
刘月光
陈如雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nulunjie Biomedical Technology Suzhou Co ltd
Original Assignee
Nulunjie Biomedical Technology Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nulunjie Biomedical Technology Suzhou Co ltd filed Critical Nulunjie Biomedical Technology Suzhou Co ltd
Priority to CN202010934192.9A priority Critical patent/CN114231489A/zh
Priority to CN202180054720.4A priority patent/CN116437943A/zh
Priority to PCT/CN2021/117302 priority patent/WO2022052964A1/zh
Priority to EP21866017.3A priority patent/EP4212624A4/en
Priority to US18/024,504 priority patent/US20240026379A1/en
Priority to JP2023515253A priority patent/JP7680072B2/ja
Priority to KR1020237011913A priority patent/KR20230082024A/ko
Publication of CN114231489A publication Critical patent/CN114231489A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202010934192.9A 2020-09-08 2020-09-08 用于重编程的功能性片段、组合及其应用 Pending CN114231489A (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202010934192.9A CN114231489A (zh) 2020-09-08 2020-09-08 用于重编程的功能性片段、组合及其应用
CN202180054720.4A CN116437943A (zh) 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用
PCT/CN2021/117302 WO2022052964A1 (zh) 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用
EP21866017.3A EP4212624A4 (en) 2020-09-08 2021-09-08 FUNCTIONAL FRAGMENT FOR REPROGRAMMING, ASSEMBLY AND APPLICATION THEREOF
US18/024,504 US20240026379A1 (en) 2020-09-08 2021-09-08 Functional fragment for reprogramming, composition, and application thereof
JP2023515253A JP7680072B2 (ja) 2020-09-08 2021-09-08 リプログラミング用機能性断片、組み合わせ、およびその用途
KR1020237011913A KR20230082024A (ko) 2020-09-08 2021-09-08 재프로그래밍을 위한 기능적 단편, 구성 및 이의 응용

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010934192.9A CN114231489A (zh) 2020-09-08 2020-09-08 用于重编程的功能性片段、组合及其应用

Publications (1)

Publication Number Publication Date
CN114231489A true CN114231489A (zh) 2022-03-25

Family

ID=80632100

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010934192.9A Pending CN114231489A (zh) 2020-09-08 2020-09-08 用于重编程的功能性片段、组合及其应用
CN202180054720.4A Pending CN116437943A (zh) 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180054720.4A Pending CN116437943A (zh) 2020-09-08 2021-09-08 用于重编程的功能性片段、组合及其应用

Country Status (6)

Country Link
US (1) US20240026379A1 (https=)
EP (1) EP4212624A4 (https=)
JP (1) JP7680072B2 (https=)
KR (1) KR20230082024A (https=)
CN (2) CN114231489A (https=)
WO (1) WO2022052964A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117070477A (zh) * 2022-05-10 2023-11-17 纽伦捷生物医药科技（上海）有限公司 重组溶瘤病毒的重编程的功能性片段、组合及其应用
WO2025108407A2 (en) 2023-11-23 2025-05-30 Neuexcell Therapeutics (Suzhou) Co., Ltd. Gene therapy compositions and methods for treating glioma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053522A2 (en) * 2008-10-29 2010-05-14 The Regents Of The University Of California Methods for identifying and producing neural stem and progenitor cells and their progeny
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US9057053B2 (en) * 2010-01-19 2015-06-16 The Board Of Trustees Of The Leland Stanford Junior University Direct conversion of cells to cells of other lineages
EP2531599A4 (en) * 2010-02-04 2014-01-08 Vivoscript Inc COMPOSITIONS AND METHODS OF RENEWING CELLS WITHOUT GENETIC MODIFICATION FOR THE TREATMENT OF NEUROLOGICAL SUFFERING
WO2014037527A1 (en) * 2012-09-07 2014-03-13 Cambridge Enterprise Limited Maturation of mammalian cells by modulation of protein phosphorylation
US10076574B2 (en) 2013-10-25 2018-09-18 Wayne State University Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
EP3099786A1 (en) * 2014-01-29 2016-12-07 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Trans-differentiation of differentiated cells
WO2017081033A1 (en) * 2015-11-09 2017-05-18 Universite De Nice Sophia Antipolis Cell differentiation or reprogramming using fezf2 and lmo4
CN107435050B (zh) * 2017-06-20 2021-02-09 向孟清 一种将人或动物体细胞诱导为神经干细胞的方法
EP3418378B1 (en) * 2017-06-22 2024-12-25 HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ Novel methods for the generation and use of human induced neural border stem cells
US20200018746A1 (en) * 2018-03-14 2020-01-16 The Broad Institute, Inc. Three-Dimensional Human Neural Tissues for CRISPR-Mediated Perturbation of Disease Genes
US20210228741A1 (en) * 2018-04-27 2021-07-29 University Of Washington Methods and compositions to stimulate retinal regeneration
US20200002679A1 (en) * 2018-06-05 2020-01-02 Kcellbio Banking Co., Ltd. Composition for cell regeneration comprising cells hypersecreting growth factors, and at least one of neural stem cells, neurons and gabaergic neurons
US20210268126A1 (en) * 2018-08-23 2021-09-02 Rutgers, The State University Of New Jersey Treating spinal cord injury (sci) and brain injury using gsx1
CN109385404B (zh) * 2018-10-19 2021-07-06 国典(北京)医药科技有限公司 一种诱导干细胞分化为神经元的方法及神经元与应用

Also Published As

Publication number Publication date
JP7680072B2 (ja) 2025-05-20
JP2023540130A (ja) 2023-09-21
KR20230082024A (ko) 2023-06-08
EP4212624A1 (en) 2023-07-19
WO2022052964A1 (zh) 2022-03-17
CN116437943A (zh) 2023-07-14
EP4212624A4 (en) 2024-12-18
US20240026379A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
Qin et al. Cross-talk between KLF4 and STAT3 regulates axon regeneration
CN109069544B (zh) 脑内生成gaba能神经元
JP6960396B2 (ja) 分裂終了細胞の細胞分裂を誘発するための方法
Hankins et al. Harvey and Kirsten sarcoma viruses promote the growth and differentiation of erythroid precursor cells in vitro
Mukhamedshina et al. Adenoviral vector carrying glial cell-derived neurotrophic factor for direct gene therapy in comparison with human umbilical cord blood cell-mediated therapy of spinal cord injury in rat
KR20210133227A (ko) 뉴런 세포 흥분성을 정상화하고 드라베 증후군을 치료하기 위한 개재뉴런-특이적 치료제
WO2021031810A1 (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
CN112386699A (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
CN114231489A (zh) 用于重编程的功能性片段、组合及其应用
EP4458955A1 (en) Factor for direct conversion of motor nerve cells
WO2021032068A1 (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
CN113652402A (zh) 一种诱导胶质细胞转分化为功能性神经元的方法及其应用
US11827884B2 (en) Core master regulators of glioblastoma stem cells
US20090281163A1 (en) Regulatory elements that mediate retinal cell-specific gene expression
KR20240032021A (ko) 신경 재프로그래밍을 위한 방법 및 조성물
CN117279668A (zh) 胶质细胞向神经元转分化用于预防或治疗神经元功能缺失或死亡相关疾病
WO2019027298A9 (ko) Trail 및 cd를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 암의 예방또는 치료용 약학 조성물
HK40097397A (en) Functional fragment for reprogramming, composition, and application thereof
US20260061077A1 (en) Methods and compositions of treating retinal degenerative diseases
Wang et al. Polyomaviruses and cancer-interplay between viral proteins and signal transduction pathways
CN114272378B (zh) 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途
Wu et al. Müller glia cell cycle re-activation by simultaneous cyclin D1 overexpression and p27kip1 knockdown promotes retinal regeneration in mice
CN112292134A (zh) Mir-17~92作为运动神经元(mn)退化疾病的治疗或诊断目标
CN111358959B (zh) Roquin1蛋白及其编码基因在制备抑制肿瘤的药物中的应用
JPWO2022052964A5 (https=)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220325

WD01 Invention patent application deemed withdrawn after publication